Sifrol ER

Sifrol ER



Boehringer Ingelheim


Concise Prescribing Info
Pramipexole dihydrochloride monohydrate
Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa.
Dosage/Direction for Use
Parkinson's disease Dose escalation: 0.125 mg tds on wk 1, followed by 0.25 mg tds on wk 2 then 0.5 mg tds on wk 3. If necessary, increased by 0.75 mg at wkly intervals to max: 4.5 mg daily. Maintenance: 0.375-4.5 mg daily. During dose escalation in pivotal studies, efficacy was observed starting at 1.5 mg daily dose. Patient on levodopa Reduce dose. Renal impairment CrCl 30-50 mL/min Initially 0.375 mg every other day. If necessary, may be increased by 0.375 mg at wkly intervals to max: 2.25 mg daily.
May be taken with or without food: Take at about the same time each day. Swallow whole, do not chew/divide/crush.
Special Precautions
Sudden sleep onset & somnolence. Hallucinations, abnormal behaviour (reflecting symptoms of impulse control disorders & compulsive behaviours) eg, binge eating, compulsive shopping, hypersexuality & pathological gambling); psychotic disorders; severe CV disease; dystonia; melanoma; rhabdomyolysis; stool remnants. Closely monitor during tapering & discontinuation due to dopamine-agonist w/drawal syndrome (DAWS). Regularly monitor ophth & BP during treatment. Avoid abrupt w/drawal. Augmentation in RLS. Not recommended to co-administer w/ antipsychotics. Concomitant use w/ other sedatives or alcohol. May affect ability to drive & use machines. Renal impairment. Pregnancy. Not to be used during lactation. Paed patients.
Adverse Reactions
Pneumonia; inappropriate antidiuretic hormone secretion; abnormal behaviour & dreams, confusion, delusion, hallucinations, hyperphagia, insomnia, libido disorders, paranoia, restlessness; amnesia, antecollis, dizziness, dyskinesia, headache, hyperkinesia, somnolence, sudden sleep onset, syncope; visual impairment eg, diplopia, blurred vision & reduced visual acuity; cardiac failure; hypotension; dyspnoea, hiccups; constipation, nausea, vomiting; hypersensitivity, pruritus, rash; fatigue, peripheral oedema, DAWS; decreased wt & appetite, increased wt.
Drug Interactions
Reduced clearance w/ basic cationic drugs eg, cimetidine. Possible interaction w/ amantadine. Not recommended to co-administer w/ antipsychotics. Possible additive effects w/ other sedatives or alcohol.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BC05 - pramipexole ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
Sifrol ER XR tab 0.375 mg
Sifrol ER XR tab 1.5 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in